IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2026
Aggregated presentation by day and by market
| Purchases of own shares from June 1st to June 5th 2026 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/06/2026 | FR0010259150 | 6 000 | 153,1130 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 02/06/2026 | FR0010259150 | 3 000 | 151,6046 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 03/06/2026 | FR0010259150 | 3 000 | 150,2304 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 04/06/2026 | FR0010259150 | 1 881 | 152,4239 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/06/2026 | FR0010259150 | 2 386 | 156,1763 | XPAR |
| TOTAL | 16 267 | 152,6728 | ||||
Attachment

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2026
Aggregated presentation by day and by market
| Purchases of own shares from June 1st to June 5th 2026 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/06/2026 | FR0010259150 | 6 000 | 153,1130 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 02/06/2026 | FR0010259150 | 3 000 | 151,6046 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 03/06/2026 | FR0010259150 | 3 000 | 150,2304 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 04/06/2026 | FR0010259150 | 1 881 | 152,4239 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/06/2026 | FR0010259150 | 2 386 | 156,1763 | XPAR |
| TOTAL | 16 267 | 152,6728 | ||||
Attachment

Related stories
Quand les acides biliaires prennent une dimension plus large : comment la biologie de la cholestase transforme la recherche sur les maladies hépatiques rares
Tester l’hypothèse : un pilote ciblé sur l’IA dans le domaine de la santé
Toujours une longueur d’avance : Anne Petit et l’art de concrétiser les médicaments
Related Press Releases
Ipsen provides update on Phase III BOLD trial in biliary...
Ipsen – Corrective statement amending the monthly disclosure of the...
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset...
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – June 2026 – Monthly information relative to the...
Ipsen – Half year statement – 2026 06 30
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus...